CAPE TOWN, South Africa, and SANTA CLARA, Calif., Aug. 02, 2017 -- Wisepill Technologies, a leading provider of medication adherence management solutions, and Aeris, a pioneer and leader in the Internet of Things (IoT), today announced they are collaborating to help pharmaceutical businesses and healthcare organizations around the world improve medication management for their patients through IoT-enabled smart pillboxes.
|
|||||
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/f2f6dc00-8175-4648-b7d1-1764c03cc839
Wisepill Technologies is the creator of the Wisepill dispenser, a pillbox with a global systems for mobile communications (GSM) chip that uses a mobile phone and IoT technologies enabled by Aeris to provide real-time medication management solutions. Aeris IoT Connectivity services offers many features to provide Wisepill with the opportunity to enhance service delivery and increase service radius.
Wisepill was founded in 2007 by Lloyd and Ricci Marshall to tackle the challenging problem of medication non-adherence in both developed and developing countries. The Wisepill dispenser was designed so that it would be easy to use. A number of independent user surveys have shown that people benefit from using the dispenser and appreciate the support they receive via the service and reminders.
The Wisepill electronic pillbox monitors patient adherence and provides instant feedback via cellular and IoT technologies. Unlike many reminder systems on the market that nag users to take their medicine, the Wisepill system was created to remind users only when they forget.
Wisepill has been used by patients with tuberculosis, human immunodeficiency virus (HIV), epilepsy, osteoporosis, chronic heart conditions, diabetes, leukemia, asthma, attention deficit hyperactive disorder (ADHD), and hepatitis C in more than 20 countries. The Family Health International chose Wisepill for its Truvada clinical trials. This was the first time that anti-retro viral drugs were used as a pre-exposure prophylaxis treatment for high-risk HIV patients.
The Wisepill system also has been used by research organizations and universities to monitor adherence for research purposes. Wisepill has worked with Massachusetts General Hospital and the Harvard Initiative for Global Health to adapt the technology to work well in a rural environment where cellular networks are not always reliable.
CLICK TO TWEET: .@Wisepill & @AerisM2M team up to advance #IoT medication adherence via IoT-enabled #smartpillbox. #AerisIoT http://www.aeris.com/news/
Supporting Quotes
- Ricci Marshall, Owner and Director, Wisepill Technologies
“Wisepill Technologies is excited to provide a truly global data solution to our clients enabled by Aeris and its IoT Connectivity services. This partnership with Aeris means that Wisepill can provide an awesome customer experience in every corner of the globe.” - Raj Kanaya, Chief Marketing Officer and Managing Director of Automotive, Aeris, and CEO, Aeris Japan
“Aeris is an Internet of Things industry leader and through our work with Wisepill Technologies we are helping enable their clients, pharmaceutical businesses and healthcare organizations around the world to use IoT technologies and improve their adherence to medication management. The combination of Aeris and Wisepill also gives patients the peace of mind knowing they are able to properly take their medication.”
Digital Assets
- [Photo] Ricci Marshall
- [Photo] Raj Kanaya
- [Image] Aeris logo
Supporting Resources
- Read about Wisepill Technologies.
- Read about Aeris.
- Read about Aeris IoT Connectivity Services.
- Read about Raj Kanaya.
- Read and subscribe to Aeris Blog and Neo Blog.
- Read Aeris news releases.
- Read about the Internet of Things FAQ.
- For more information about Aeris’ news and activities, follow the company via Twitter, LinkedIn, Google+, Facebook, Instagram, and YouTube.
About Wisepill Technologies
Wisepill is a pioneer and leader in the field of medication adherence, providing scalable real-time adherence management solutions worldwide.
About Aeris
Aeris is a technology partner with a proven history of helping companies unlock the value of IoT. For more than a decade, we’ve powered critical projects for some of the most demanding customers of IoT services. Aeris strives to fundamentally improve businesses by dramatically reducing costs, accelerating time-to-market, and enabling new revenue streams. Built from the ground up for IoT and road tested at scale, Aeris IoT Services are based on the broadest technology stack in the industry, spanning connectivity up to vertical solutions. As veterans of the industry, we know that implementing an IoT solution can be complex, and we pride ourselves on making it simpler.
For more information, contact: Kevin Petschow Aeris +1.312.985.9182 [email protected]


Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Italy Fines Apple €98.6 Million Over App Store Dominance
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



